

February 11, 2021

Market Outlook

Indian markets are likely to open with a flat to positive bias on the back of mixed global cues, led by slowing Coronavirus infections, vaccine rollouts, Budget optimism and upbeat corporate earnings.

Markets Yesterday

- Domestic markets ended flat in a volatile session as positive global cues were offset by profit booking
- US markets ended mixed tracking corporate's quarterly earnings and tech stocks


Key Developments

- For Q3FY21, Coal India reported coal offtake of 155 million tonne (MT), up 9% YoY and 15% QoQ. We expect the topline to increase 6% YoY to ₹ 24625 crore. The EBITDA margin is likely to come in at 22.0% (against 18.8% in Q2FY21 and 21.4% in Q3FY20). We expect the company to clock an EBITDA/tonne of ₹ 350/tonne (compared to ₹ 297/tonne in Q2FY21 and ₹ 350/tonne in Q3FY20)
- For Ashok Leyland, total volumes for Q3FY21 were at 33,411 units, up 7% YoY, 72% QoQ. Product mix improved in favour of M&HCVs, with MHCV: LCV ratio at ~50:50 in Q3FY21 vs. ~41:59 in Q2FY21. Consequent standalone net sales for the quarter are seen at ₹ 5,189 crore, up 29% YoY (it includes sharp price increase on account of BS-VI transition). EBITDA & EBITDA margins for the quarter are seen at ₹ 312 crore and 6%, respectively (up 320 bps QoQ on the back of operating leverage benefits). Consequent PAT is expected at ₹ 61 crore vs. ₹ 28 crore in Q3FY20

Nifty Heat Map (Not Updated - Technical Error)									
M&M	928 7.3%	Hindalco	279 6.4%	Tata Motors	336 6.3%	Shree Cement	28,022 4.9%	JSW Steel	418 3.8%
Bajaj Finserv	10,021 3.1%	Bharti Airtel	597 2.8%	Adani Ports	582 2.7%	Power Grid	213 2.6%	Tata Steel	703 2.6%
ICICI Bank	630 2.5%	GAIL	131 2.5%	Infosys	1,304 2.5%	TechM	983 2.4%	L&T	1,552 2.3%
Axis Bank	736 2.3%	Wipro	435 2.3%	Titan	1,542 2.1%	Grasim Ind	1,211 2.1%	ONGC	100 2.0%
Hero Moto	3,495 1.9%	TCS	3,214 1.8%	Asian Paints	2,417 1.7%	IOC	104 1.7%	Reliance Ind.	1,951 1.4%
Eicher	2,970 1.3%	Dr Reddy	4,860 1.2%	HCl Tech	958 1.2%	BPCL	420 1.2%	Maruti	7,575 1.1%
SBI	397 1.0%	Indusind Bank	1,035 1.0%	NTPC	100 0.8%	Nestle	17,218 0.6%	Coal India	142 0.5%
HDFC Bank	1,605 0.5%	HDFC Ltd	2,733 0.4%	HDFC Life	684 0.4%	UPL	538 0.3%	Ultratech	6,368 0.3%
Bajaj Auto	4,237 0.1%	Sun Pharma	635 0.0%	Cipla	847 -0.1%	ITC	233 -0.5%	SBI Life	859 -0.6%
Bajaj Finance	5,498 -0.7%	Divis Lab	3,782 -1.1%	Kotak Bank	1,957 -1.3%	HUL	2,237 -1.4%	Britannia	3,474 -1.9%

Today's Highlights

Results: ITC, Coal India, KNR Constructions, Petronet LNG, Ashok Leyland, Bosch, NCC, Gujarat Pipavav, Graphite India, Zee Media, Natco Pharma, ACC



	Close	Previous	Chg (%)	MTD(%)	YTD(%)
Sensex	51,309	51,329	0.0	10.9	7.5
Nifty	15,107	15,109	0.0	10.8	8.0


Institutional Activity					
	CY19	CY20	YTD CY21	Yesterday	Last 5 Days
FII (₹ cr)	40,893	64,379	27,540	1,787	9,097
DII (₹ cr)	44,478	-28,544	-21,020	-2,076	-4,848


World Indices – Monthly performance					
Nasdaq	NSE	Nikkei	BSE	Shanghai	
13,973	15,107	29,563	51,309	3,655	
5.8%	5.3%	5.1%	4.1%	2.4%	
Dow Jones	France	Germany	Kospi	U.K.	
31,438	5,671	13,933	3,101	6,524	
1.1%	0.2%	0.0%	-1.6%	-4.0%	


Markets Today (Not Updated – Technical Error)						
Commodities	Close	Previous	Chng (%)	MTD(%)	YTD(%)	
Gold (₹/10 gm)	47,312	47,256	0.1	-3.6	-5.7	
Silver (₹/kg)	68,855	68,738	0.2	-1.2	1.1	
Crude (\$/barrel)	60.0	59.3	1.0	7.3	15.7	
Copper (\$/tonne)	7,927	7,826	1.3	0.8	2.3	
Currency						
USD/INR	73.0	73.0	-0.1	0.0	0.1	
EUR/USD	1.2	1.2	-0.2	-0.9	-1.6	
USD/YEN	105.7	105.9	-0.3	-0.9	-2.3	
ADRs						
HDFC Bank	82.0	79.8	2.8	13.7	13.4	
ICICI Bank	17.6	17.4	1.2	16.3	18.2	
Tata Motors	21.5	22.3	-3.5	20.9	71.0	
Infosys	17.6	17.6	0.2	4.4	4.0	
Dr Reddys Labs	65.6	63.5	3.3	7.0	-8.0	
Wipro	6.4	6.5	-0.3	4.6	13.8	




Key Economic Indicator	Period	Latest	Prior Values
RBI Cash Reserve Ratio	N/A	3.00%	3.00%
RBI Repo Rate	N/A	4.00%	4.00%
RBI Reverse Repo Rate	N/A	3.35%	3.35%
CPIYY	Dec	4.59%	6.93%
Current Account Balance	02	15.5bln \$	19.8bln \$
Exports - USD	Dec	26.9 bln\$	23.5 bln\$
FX Reserves, USD Final	Jan	590 bln\$	585 bln\$
GDP Quarterly yy	0.2	-7.50%	-23.90%
GDP Annual	FY20	4.20%	6.10%
Imports - USD	Dec	42.6 bln \$	33.4 bln \$
Industrial Output yy	Nov	-1.90%	3.60%
Manufacturing Output	Nov	-1.70%	3.50%
Trade Deficit Govt - USD	Dec	-15.7bln \$	-9.9bln \$
WPI Food yy	Dec	-1.11%	3.94%
WPI Fuel yy	Dec	-8.72%	-9.87%
WPI Inflation yy	Dec	1.22%	1.55%
WPI Manuf Inflation yy	Dec	4.24%	2.97%







Sectoral Performance – Monthly Returns (%) (Not Updated)



Company/l ndustry	News	View	Impact
Hindalco	Hindalco's India business posted a healthy set of operational numbers in Q3FY21. The topline of India business was at ₹ 11425 crore (up 11% YoY, 19% QoQ). EBITDA of India business was at ₹ 1528 crore (up 17% YoY, 20% QoQ, higher than our estimate of ₹ 1413 crore). EBITDA margin came in at 13.4% compared to 12.7% in Q3FY20 and 13.3% in Q2FY21. Ensuing PAT for India business was at ₹ 495 crore (up 90% YoY, 51% QoQ), higher than our estimate of ₹ 358 crore	prices both QoQ as well as YoY aided Q3FY21 performance. For Q3FY21, the aluminium segment posted sales volume of 315000 tonnes, broadly in line with our estimate of 319000 tonnes while the copper segment reported sales volume of 73000 tonnes (our estimate of 73000 tonnes). The EBITDA margin in the	



Titan Company

As guided by the management in its pre-The healthy growth revival depicts the quarterly update, the jewellery division inherent strength of the Tanishq brand and witnessed strong revival with revenue growth continuous focus on market share gains. of 16% YoY in Q3FY21. Share of studded Revenue trajectory accelerated further in ratio witnessed sequential improvement January with jewellery division witnessing however still below pre-Covid (Q3FY21: 26%, Q3FY20: 29%). Watches studded ratio. Revival in share of studded segment to witnessed strong recovery, with ratio augurs well for overall margin profile revenue recovery rate reaching at 88% in Q3FY21 vs. 55% in Q21FY21. Overall revenues arew 17% YoY to ₹ 7619.0 crore (Idirect estimate: ₹ 7490.7 crore). The company reported EBITDA margins of 11.1% (down 50 bps YoY, I-direct estimate: 12.0%). Absolute EBITDA grew 12% YoY to ₹ 848.0 crore (Idirect estimate: ₹ 898.1 crore). On account of steady operational performance PAT grew 12% YoY to ₹ 530.0 crore (I-direct estimate: ₹ 579.1 crore)

levels 28% YoY growth driven by 16% growth in



Aurobindo Pharma

crore led by 13.2% YoY growth in Europe Q3FY21 numbers. Adjusting for certain formulations business to ₹ 1671 crore. US one-off exceptional items, results were in business grew 6.8% YoY to ₹ 3172 crore. line with I-direct estimates on all fronts. ARV segment grew 41.5% YoY to ₹ 443 crore. Aurobindo possesses one of the best RoW markets posted growth of 14.5% YoY to enduring generics ecosystem among ₹ 396 crore. However, API segment de-grew|peers (vertically integrated model, lower 13.6% YoY to ₹ 682 crore. EBITDA margins product concentration) to withstand the grew 101 bps YoY to 21.5% with higher gross volatility in the US generics space. The margins being partly offset by higher other company has also significantly improved expenditure. EBITDA grew 13.3% YoY to ₹its net debt position from foregoing the 1369 crore against I-direct estimates of ₹ 1374 Sandoz deal and from the sale of its Natrol crore. Adjusted PAT grew 16.4% YoY to ₹ business. We will get more detials post the 836.5 line with crore in performance and higher other income. Exceptional items for Q3FY21 were at ₹ 2814 crore, which included 1) sale of Natrol business, 2) equity interest remeasurement gain in Eugia and 3) certain impairment charges taken amid Covid-19

Q3FY21 revenues grew 8.0% YoY to ₹ 6365 Aurobindo Pharma posted a good set of operational conference call



Gail India

Gail's revenues fell 13% YoY to ₹ 15456.8 Gail's crore in Q3FY21. Gas transmission and volumes reached pre-Covid level during petchem segments' performance was better the than expected while gas trading and LPG/LLH performance also supported profitability. performance was weaker than anticipated. However, sustained profits in future will be Subsequently, EBITDA was at ₹ 1919.5 crore, important. Profitability of the gas trading down 7.4% YoY). The company reported segment, which has been a drag on overall higher than expected other income of ₹ 470.8 performance, may provide some relief in crore. Reported PAT was at ₹ 1487.3 crore, up the coming quarter due to increase in spot 18.9% YoY as profitability was also aided by LNG prices lower tax outgo

gas transmission and trading quarter. Petchem seament's





Opening Bell ICICI Direct Research Page Revenue for the guarter grew 17% YoY to ₹ The management indicated that Industries 927.1 crore (up 25% QoQ; I-direct estimate: ₹ continues to witness increasing trend in 890.7 crore). Currently 94% of MBOs, 100% sales particularly in e-commerce channel EBOs and 93% of LFS are operational. Strong and the athleisure product category. topline growth coupled with tight leash on Liquidity position remained strong with operating overheads (employee & other cash & cash equivalents increasing 23% expenses as percenatge to sales down 119 QoQ to ₹ 494 crore post repayment of bps and 344 bps YoY, respectively) resulted debt. The company declared a second in robust EBITDA margin expansion of 690 interim dividend of ₹ 150/share bps YoY to 24.4% (I-direct estimate: 21.1%). 250/share in YTDFY21) Absolute EBITDA grew 63% YoY to ₹ 226.1 crore (I-direct estimate: ₹ 188 crore). Driven by healthy operational performance and higher other income (up 19% YoY to ₹ 4.2 crore), PAT grew 77% YoY to ₹ 153.7 crore (Idirect estimate: 125.4 crore) Bata India Bata reported revenue de-growth of 26% Bata continues to penetrate in newer YoY to ₹ 614.7 crore (vs. estimated de-growth towns through franchise operated stores of 32% YoY). Aligning with the current opened 45 stores during the quarter demand scenario, Bata has tweaked its taking total store count to 221 franchise product portfolio from formals & Fashion stores). Formal and fashion footwear categories to Casuals, Fitness, & Essential demand is likely to remain muted in the categories covering comfortable sneakers, near term due to fewer social gatherings. open & sandals styles. This has led to faster Unfavourable product mix (shift towards pick up in volumes (reached 88% of pre-covid casual category) may lead to deterioration levels). Gross margins continued to contract in gross margins in the near term. sharply by \sim 910 bps YoY to 51.5% (I-direct However, cost rationalisation initiatives 54.0%) mainly owing to will benefit the company over the longer unfavourable product mix. Subsequently, term. We believe that with its strong brand EBITDA margins declined 1260 bps YoY to patronage and pan-India retail reach, Bata 19% (I-direct estimate: 20%, Q2FY21: 5%). India should be able to revive its revenue Absolute EBITDA declined 55% YoY to ₹ 117 growth trajectory as and when the impact crore (I-direct estimate: 114 crore, Q2FY21: ₹ of the Covid-19 is phased out 18.1 crore) Wabco Wabco India reported a healthy Q3FY21 The company's performance tracks recent India performance. Topline grew 29% YoY to ₹ 566 improvement in domestic M&HCV space. crore while margins improved 40 bps QoQ to Margin improvement was particularly 15.5%. Consequent PAT was up 35% YoY to encouraging as it encompassed ~450 bps ₹52 crore sequential decline in employee and other expenses on percentage of sales basis, operating leverage benefits, with gross

margins contracting ~420 bps QoQ. Expectations of the Indian CV market having turned a corner should hold Wabco, as the leader in the CV braking

space, in good stead, going forward



P&G Health	While P&G Health's Q2FY21 (July-June fiscal year) revenues were flattish (up just 1.5% YoY) to ₹ 240 crore, EBITDA margins jumped significantly from 20.7% in Q2FY20 to 36.9% due to significantly lower other expenditure and higher gross margins. EBITDA grew 81.0% YoY to ₹ 89 crore. Net profit grew 77.6% YoY to ₹ 68 crore in line with a robust operational performance	margin performances in the recent past resulting in strong profitability. Besides possessing MNC pharma traits like strong brand stickiness, growth, earnings visibility, strong b/s etc, the key differentiator for PGHL is that its core	
Suven Pharma	Suven Pharma reported exemplary Q3FY21 results with revenues growing 53.8% YoY to ₹ 275 crore. More importantly, the company clocked an EBITDA margin of 50.2% (up 568 bps YoY) in the quarter on the back of better operational leverage. Subsequently, EBITDA grew 73.5% to ₹ 138 crore. PAT nearly doubled YoY to ₹ 114 crore	on all fronts. Despite the pandemic situation, the company had guided for 15-20% growth earlier based on strong order book position. We expect free cash flow to remain strong on the back of the	
TTK Prestige	TTK reported robust revenue growth of 24.4% YoY to ₹ 679.4 crore (I-direct estimate: ₹ 612.8 crore). Growth was broad based with cooker (30% of sales), cookware (15% of sales) and appliances (51% of sales) categories registering strong revenue growth of 29%, 34% and 19% YoY, respectively. owing to positive operating leverage, TTK reported one of its all-time high EBTDA margins of 17.4% (up 220 bps YoY). Absolute EBITDA grew by 42% YoY to ₹ 118.2 crore (I-direct estimate: ₹ 96.2 crore). On the back of healthy operational performance, ensuing PAT increased by 42% YoY to ₹ 86.5 crore (I-direct estimate: ₹ 70 crore)	(large format channels). Revenue trajectory continues to be on an uptrend with company registering 20% YoY revenue growth in January 2021. Company's plan to augment its manufacturing capacities with additional lines without significant capex outlay is progressing as per schedule. With supply side issues mostly resolved and opening up of all distribution channels, we expect revenue growth trajectory momentum to	
Nirlon	Nirlon reported stable numbers. Topline at ₹ 80.1 crore was up 5% YoY, while EBITDA at 61.1 crore, was up ~7% YoY. PAT was up 20% YoY at ₹ 32.8 crore, also aided by capitalisation of interest.	risk on major tenant exits or non-renewals. With collections at 99% and upcoming	



Greaves Cotton	Greaves Cotton (GRV) reported standalone revenues at ₹ 436.8 crore, which declined by 11.7% on YoY, (above our estimates of ₹ 353.1 crore). The engine segment revenues came in at ₹ 412 crore which declined by 7.5% YoY. On the other hand, E-Mobility segment revenue grew by 47.4% to ₹ 57.8 crore owing to decent growth registered in Ampere E-2W and ELE e-rickshaws. EBITDA declined by 30.3% to ₹ 53.8 crore on YoY (above our estimates of ₹ 33.9 crore). EBITDA margins declined by 330bps to 12.3% (Vs our estimate of 9.6%) impacted by higher operating expenses and lesser revenue booking. The company has reported Adj. PAT (Adjusted for exceptional item) at ₹ 31.5 crore, down by 37.6% on YoY basis.	business continues to remain a key concern on the back of BS VI transitions and impact on shared mobility space due to pandemic. The E-mobility business registered decent growth and other segments (Non-Auto, Aftermarket) have reached back to pre-covid levels. While Bestway acquisition would expand E-3-W base, new product launches in high speed E-2W vehicles at Ampere and new business initiatives (CNG engines, after market and B2C business) may provide much needed growth uptick in the long term.	\Leftrightarrow
Anup Engineerin g	Anup Engineering announced a buyback through open market stock exchange mechanism. The maximum amount allocated for the buyback is ₹ 25 crore (excl transaction cost) with maximum price being ₹ 800 per share. The actual number of shares bought back will depend on actual market price at which the market buyback was done.	crore in FDs. The company's decision to opt for a buyback and reward shareholders bodes well for the stock given the company has sufficient balance left (~₹ 50 crore) for capex needs.	
-	IGL's topline declined 13.1% YoY to ₹ 1446.2 crore in Q3FY21 due to lower sales volumes. The volumes stood at 6.3 mmscmd, down 6.5% YoY . Gross margins increased ₹ 2.8/scm YoY and ₹ 0.8/scm QoQ to ₹ 14.4/scm due to lower gas costs. Subsequently, EBITDA was at ₹ 500.7 crore, up 27.8% YoY. On the profitability front, PAT was up 18% YoY to ₹ 334.9 crore.	sequential basis but yet to fully recover. Industrial/commercial PNG demand has recovered and grew above pre-Covid level. Full recovery in CNG demand coupled with steady margins will be	\Leftrightarrow
Gujarat State Petronet (GSPL)	GSPL's operating revenue fell 7.2% YoY to ₹ 580.8 crore in Q3FY21. Transmission volumes improved 6.6% YoY (down 1% QoQ) to 39.4 mmscmd. EBITDA was at ₹ 398.4 crore, up 4.8% YoY. Subsequently. reported PAT stood at ₹ 247.5 crore, up 11.4% YoY	transmission volumes slightly moderated in Q3. However, volumes remain higher YoY. CGD volume offtake has improved	\Leftrightarrow





Entertainm ent Network (ENIL)	ENIL's operating revenue fell 42.3% YoY to ₹ 85.6 crore in Q3FY21. Although company managed cost saving on all fronts, EBITDA was at ₹ 20.9 crore, down 49.5% YoY owing to weaker topline. The company reported exceptional items of ₹ 29.3 crore as a result of writeback of performance royalty liability (₹ 26.7 crore) and fee receiving post termination of time brokerage deal with a US broadcaster (₹ 2.6 crore). Subsequently, reported PAT stood at ₹ 18.4 crore, up 85.9% YoY	to by in er. nd he hy ek
Magma Fincorp	Adar Poonawalla controlled Rising Sun Holdings, will acquire 60% stake in Magma Fincorp. Magma will get fresh capital of ₹3,456 crore. Existing promoters will infuse ₹ 250 crore and Poonawalla's will bring in about ₹3,200 crore as capital. Magma will allot 45.8 crore shares to Rising Sun Holdings, and 3.5 crore shares to Sanjay Chamaria and Mayank Poddar. Preferential allotment represents 64.68% of MFL's enhanced equity share capital post issue. Rising Sun Holding would hold 60.0% stake in entity post issue and existing promoter group stake would get reduced to 13.3%. Net Worth of Magma Fincorp shall increase to over ₹6,300 crores post issue.	ng tal

Key developments (Continued...)

- We expect Petronet LNG's topline to decline 14.8% YoY to ₹ 7591 crore. Total volumes are expected to increase 10.4% YoY to 257 trillion British thermal units (tbtu) (~4.9 MMT) on account of higher regas volumes. On a QoQ basis, volumes are expected to increase 1.3%. Blended margins are expected at ₹ 54.8/mmbtu, down 1.1% YoY and down 8.1% QoQ as an increase in spot LNG prices would lead to a decline in trading margins. Subsequently, PAT is expected at ₹ 761.7 crore, an increase of 12.8% YoY and decline of 17.9% QoQ
- KNR Construction to report Q3FY21 numbers today. We expect revenues to grow 11% YoY to ₹ 619 crore, as execution has remained stable and further boosted by improved labour availability. EBITDA margin is expected to contract 330 bps YoY to 19%, given higher base owing to irrigation revenues. Overall, we expect bottomline to grow 34.9% YoY to ₹ 54.2 crore, given lower interest and tax and one-off impairment of ₹ 6 crore investment in Walayar project in the base quarter. Key Monitorable: Status on HAM projects, recovery of Telangana irrigation receivables
- For Q3FY21E, on a consolidated basis, we expect Graphite India (GIL) to report capacity utilisation of 75% (45% in Q3FY20 and 60% in Q2FY21). For the quarter we expect Graphite India to report a consolidated topline of ₹ 545 crore (down 15 YoY, however up 12% QoQ). We expect the company to report consolidated EBITDA of ₹ 27 crore and consolidated net profit of 50 crore
- NCC to report Q3FY21 numbers today. We expect topline to grow 4% YoY to ₹ 2202 crore, at lower end of guidance of ~₹ 2200-2300 crore given by the company, led by improving labour availability and execution. EBITDA margin is expected at 12%, (up 20 bps YoY), NCC impairment of investments worth ~₹ 23 crore and reversal of prior period tax of ~₹ 73 crore in the base quarter. Therefore, optically the reported PAT will decline 14% YoY to ₹ 94.5 crore. Adjusted PBT, however, is likely to grow ~36% YoY. Key Monitorable: Management commentary on order inflows, execution, status on Andhra Pradesh orders, receivables and net debt

Key developments (Continued...)


- Eicher Motors' (EML) posted decent Q3FY21 results. Consolidated revenues stood at ₹ 2,828 crore (up 19.3% YoY), tracking Royal Enfield (RE) volume increase of ~9% YoY to ~2 lakh units and flat ASPs QoQ at ₹ 1.4 lakh/unit. EBITDA margins at 23.8% were higher by 168 bps sequentially on the back of operating leverage benefits, with gross margins depleted by ~110 bps QoQ. Consequent consolidated PAT stood at ₹ 533 crore (up 6.8% YoY), with share of profits from VECV JV stood at ₹ 31.4 crore
- Hind Rectifiers (HRL) reported a mixed set of numbers for Q3FY21. It reported revenues at ₹ 81 crore which grew by 15.4% on YoY aided by gradual revival of supply chain and reviving business activities amid economic recovery. EBITDA came in at ₹ 4.9 crore, down 41% on YoY basis impacted by decline in gross margin. EBITDA margins for Q3FY21 declined by 570bps on YoY to 6.0%. However, gross margins for Q3FY21 declined by 810bps to 21.8% on YoY basis owing to significant increase in raw material cost while other operating expenses registered a decline of 18.8% to ₹ 4.3 crore, on YoY basis. HRL reported PAT at ₹ 1.3 crore which declined by 66.1%, YoY partly impacted by lower other income, increase in interest expense
- Esab India reported a mixed set of numbers for Q3FY21. While Revenue grew by 8.7% to ₹ 183.9 crore amid revival seen in infrastructure, automotive, engineering and metals sectors, EBITDA margins contracted by 310bps to 10.7% owing to increased raw material cost and product mix. PAT came in at ₹ 14.7 crore which declined by 17.2%, YoY factoring in higher effective tax rate and lower other income. Other income came in at ₹ 3.1 crore with a decline of 13.2% on YoY basis
- Shree Pushkar chemical reported muted set of numbers. Revenues remained at ₹ 71.87 crore against ₹ 71.84 crore in Q3FY20. We believe since there has been increase in the dye intermediate prices, the growth should be higher. Further, better sales from SSP should also have augured well for the performance however the same seems missing. OPM contracted by 192bps YoY to 15.72% leading to EBITDA decline of 10.8% YoY to ₹ 11.3 crore. PAT was down by 9.9% YoY to ₹ 8.07 crore
- Happiest Minds reported Q3FY21 numbers. The company's revenues increased 6.0% QoQ (up 8.8% YoY) to US\$26 million mainly led by growth in Infrastructure Management & Security Services (up 9.4% QoQ) and Digital Business Solution (up 5.8% QoQ). The company's EBITDA margin increased 337 bps QoQ to 29.7% mainly led by higher utilisation. The company's PAT increased 23.7% QoQ to ₹ 42 crore
- India's fuel demand in January fell 3.9% YoY to 18 MMT. Diesel demand declined 2.3% YoY to 6.8 MMT while Petrol demand increased 6.1% YoY to 2.6 MMT
- CCI approves Bank of India's acquisition of 49% stake each in BOI AXA Investment Managers, BOI AXA Trustee Services. The bank had entered into a share purchase agreement with AXA Investment Managers Asia Holdings Pvt Ltd to purchase its entire 49% stake in BAIM
- Life Insurance Corp. of India (LIC) saw its claim settlement ratio deteriorate marginally in FY20 to 96.6% from 97.7% in FY19 even as private insurers increased their settlement ratio to 97.18% from 96.6% in this period. The life insurance industry in total paid 8.46 lakh claims on individual policies, with a total pay-out of ₹ 18042 crore in the FY20, data from the latest IRDAl's annual report showed
- Infosys announced that it further enhanced its collaboration with Toyota Material Handling (TMH), a North American leader in material handling innovation, to deliver an immersive experience to its dealer ecosystem on the Infosys Meridian platform. Infosys Meridian's observability and AI virtual assistant capabilities helped Toyota Material Handling to engage with dealers seamlessly through highly captivating and experiential virtual events
- State Bank of India is aiming to double its home loan book in the next five years at a time when there is intense competition in this segment with banks as well as mortgage lenders fighting it out to gain market share. SBI has crossed 5 lakh crore mark in home loan business. The bank is expecting to reach ₹ 7 lakh crore by FY2024. Currently, SBI has a market share of 34% in home loan segment among all scheduled commercial banks and is providing the most competitive rates for home loans in the market, as reported in Business standard
- Lupin's consumer healthcare division LupinLife launches 'Be One', an ayurvedic energy and immunity supplement for men
- Tata Consultancy Services (TCS) announced that it will recruit 1,500 technology employees across the UK over the next year
- Tata Starbucks has announced Sushant Dash as CEO designate effective April 1, 2021, taking over as CEO on May 1, 2021. Dash joins Tata Starbucks from Tata Consumer Products where he is currently president – packaged beverages business, India, Bangladesh, and Middle East

Nifty Daily Chart



Pivot Points						
Index/Stocks	Trend	Close	S 1	S2	R1	R2
SENSEX	Negative	51309.4	50933	50556	51600	51890
Nifty 50	Negative	15106.5	15000	14893	15191	15275
ACC Ltd	Neutral	1761.8	1738	1715	1793	1825
Axis Bank Ltd	Negative	734.8	726	716	746	756
HDFC BANK LTD	Negative	1581.8	1561	1540	1609	1636
SBI	Negative	392.3	388	383	398	403
HERO MOTOCORP LT	Positive	3539.0	3493	3448	3577	3615
MOTHERSON SUMI	Neutral	174.2	163	152	181	188
Tata Motors	Negative	328.9	321	314	335	340
M&M FIN SERVICES	Positive	190.6	185	178	197	202
BAJAJ AUTO LTD	Negative	4151.6	4097	4041	4212	4271
TCS	Negative	330.5	318	306	339	348
INDIAN OIL CORP	Negative	96.8	95	94	98	100
CIPLA LTD	Positive	863.4	847	831	873	883
PIDILITE INDS	Neutral	1757.2	1740	1722	1779	1800
Reliance Industries	Negative	1974.3	1939	1905	1997	2019
BHARTI AIRTEL	Neutral	590.2	578	566	606	621
DR REDDY'S LABS	Negative	4824.1	4762	4700	4885	4946

Nifty Call – Put Strike (Number of shares in lakh) – February, 2021



Technical Outlook

Equity benchmarks extended breather over second consecutive session and settled on a flat note at 15106, down 3 points. In the coming session, volatility would remain high owing to weekly derivative expiry sessions. However, we expect index to hold the Wednesday's low (spot-14977) and trade with a positive bias. Hence, use intraday dips towards 14986-15012 to create fresh long position for the target of 15096.

The formation of higher peak and trough on the larger degree chart signifies robust price structure that makes us confident to reiterate our positive stance on index and expect it to gradually head towards our earmarked target of 15500 in coming month. We believe, the ongoing breather amid stock specific action would help index to cool off the overbought condition and make market healthy.

The Nifty Midcap index clocked a fresh record high. However, small cap index is still ~20% away from its all-time high. Therefore, we expect small caps to witness catch up activity within broader market space

CNX Nifty Technical Picture					
Nifty 50	Intraday	Short Term			
Trend	Range Bound	Up			
Support	15040-14980	14600			
Resistance	15140-15190	15500			
20 day EMA	0	14444.0			
200 day EMA	0	12368.0			

Advances/Declines							
	Advances	Declines	Unchanged				
BSE	1406	1558	161				
NCE	004	1011	O.F.				

BSE 1406 1558 1 NSE 884 1044 Daily Technical Calls

Daily Technical Calls

- $1. \ \, \text{Buy Cipla in the range of } 863.00\text{--}865.00$
- 2. Buy M&M Financial in the range of 189.00-191.00 $\,$

All recommendations of February Future

See Momentum Pick for more details

i) CIPLA Buy CIPLA FEB Fut at ₹862.00-864.00 CMP: 865.15 Target 1: 868.9 Target 2: 879.3 Stop Loss: 855.1

ii) Eicher Motors Sell EICMOT FEB Fut at ₹2920.00-2925.00 CMP: 2903.65 Target 1:2896.8 Target 2: 2858.2 Stop Loss: 2948.2

See Derivatives view for more details



Op.	ming Den								10.0.2.00		
Results	/Events Calenda	r									
25	January Monday	26	January Tuesday	27	January Wednesday	28	January Thursday	29	January Friday	30	January Saturda
Navin fluo	•	UK Unemp	loyement Rate	Axis Bank		M&M Fin.,	Action Const.,Lupin	Mahindra	Log.,Dabur,IndusInd Bank	Dwarikesl	
_arsen &T	oubro	CH Industri	•	Digvijay C	ement,HUL	1	ect.,Maruti Suzuki,Coforge		ors, PNC Infra, Tech Mahin		
India Cem	ents			Marico, Jyo	othy Lab	KEC Int.,A	arti Ind.,Teamlease,Radico	Dr.Reddy'	s,Sun Pharma,Cipla	Shree Ce	ment,Amber
APL Apollo	o Tubes			United Sp	irits	1	bs,UBL,Eclerx,IndusTower			Relaxo,Ar	nber
				JP Retail	Sales	Tata Cher	n.,Pidilite Ind.,EIH,Granule	Grindwell,	Vedanta, Accelya	Geogit Fir	nancial
01	February Monday	02	February Tuesday	03	February Wednesday	04	February Thursday	05	February Friday	06	Februar Saturda
India Unio	n Budget 2021	HDFC.Balr	amput Chini	Ramco Ce	•	Concor.TO	CI Express,Zee Ent.,Caplin	Sumitomo	Chemical,Pfizer	JK Ceme	nt,Divi's Lab
	rolac,Mastek		Metals, Ajanta, Nocil		Corp., Inox Leisure		,Minda Ind.,Birgade,NTPC		•	BHEL	,20 200
Castrol,Zy	dus Wellness	Mangalam	Cem.,Intellect,EPL	Thermax,	PNC Infra, City Union	Hero Moto			Ador Welding	DLINK Inc	lia
MRPL			ampur Sugar,PI Ind.	Hawkins (Cooker,KPR Mill,Airtel		A Lab, Somany Cera., SBI		shoka Buildcon	Birlasoft	
US Manufa	acturing PMI	Siyaram Si	lk,Control Print	Indian Hot	tels,Astral Poly,Adani Gas	Sonata,Jir	ndal Stainless,Bajaj Electric	TCNS Clo	othing,GSK	Affle	
08	Fabruary.	09	Cohminani.	10	Cohmismi	11	Cohmien	12	Fahruany	13	Fahrus
VO	February Monday	09	February Tuesday	10	February Wednesday	- 11	February Thursday	12	February Friday	13	Februar Saturda
ABFRI To	rrent Pharma	Tata Steel	Mahanagar Gas	Hindalco I	nd.,TTK Prestige,Page Inc	Bosch NC		TV Today	,Navneet Edu., Moil	Amara Ra	ja Batteries
			•		_,Wabco India,Bata India		pavav Port,Greenply	,	,Morpen Labs.Nesco	Kalpataru	•
	n TV,Balkrishan Ind.				Minds,GAIL,NBCC,GSPL		rland,Coal India,ACC		rge,Sadbhav Eng.,Timker		
MM Forgin	g,Jagran Prakashan	Firstsource	Berger Paints,Indoco	Indraprast	ha Gas,Eicher Motors	Petronet L	NG,Zee Media,HCG		nipyard,Sunteck Realty		
Elgi Equip	ments	VST Tiller,	J&K Bank,Endurance To	Aurobindo	,P&G Healthcare,Greaves	ITC, Grap	hite India,Natco Pharma	Apollo Ho	spitals,Sobha Ltd.		
15	February	16	February	17	February	18	February	19	February	20	Februar
	Monday	10	Tuesday	.,	Wednesday		Thursday		Friday		Saturda
IN WPI Inf	•	Varun Beve	erages, Nestle India	UK CPI Y		Ambuja C		Mahindra	•		
EU Trade	Balance	JP Exports	YoY		ruction Output	EU CPI Y	Yc	EU Manuf	acturing PMI		
IN WPI Ma	anufacturing Inflation	JP Imports		US PPI		1	mer Confidence		ng Home Sales		
		JP Trade B	alance	US Retail		JP Manufa	acturing PMI		acturing PMI		
				US Capac	ity Utilisation			US Manuf	acturing PMI		
22	February	23	February	24	February	25	February	26	February	27	Februar
	Monday		Tuesday		Wednesday		Thursday		Friday		Saturda
US Chicag	go Fed Activity	Sanofi India	a	US New H	lome Sales	US GDP(0	•		l Fiscal Deficit		acturing PM
_			nsumer Confidence				mer Confidence		luarterly(YoY) (Q1)	CH Non-N	Manufacturin
			loyment Rate			JP Industr	ial Production		ructure Output(YoY)		
		Huhtamaki	inuia						s Trade Balance ruction Orders		
		1						JE COURT	uction Olders		

Major Economic Events this Week						
Date	Event	Country	Period	Actual	Expected	
09-Feb	CPI YoY	CH	Jan	-0.3%	0.2%	
09-Feb	PPI YoY	CH	Jan	0.3%	-0.4%	
10-Feb	CPI(MoM)	US	Jan	0.3%	0.3%	
10-Feb	Crude Oil Inventories	US	Jan	-6.44M	-0.994M	
10-Feb	Federal Budget Balance	US	Jan	163.0B	-144.0B	
Date	Event	Country	Period	Expected	Previous	
11-Feb	Initial Jobless Claims	US	Jan	750k	779K	
12-Feb	GDP QoQ	UK	Jan	0.5%	16.0%	
12-Feb	Industrial Production	EU	Jan	-	2.5%	
12-Feb	Manufacturing Production	UK	Jan	0.7%	0.7%	
12-Feb	Bank Loan Growth	US	Jan	-	6.4%	
12-Feb	Deposit Growth	IN	Jan	-	11.4%	
12-Feb	FX, Reserves USD	IN	Jan	-	585.33B	
12-Feb	CPI YoY	IN	Jan	4.4%	4.6%	
12-Feb	Industrial Production	IN	Dec	-0.2%	-1.9%	
12-Feb	Manufacturing Output	IN	Dec	-	-1.7%	

Result Preview									
Company Crore	Revenue Q3FY21E	Chg(%	•	EBITDA Q3FY21E	Chg(%) YoY	QoQ	PAT Q3FY21E	Chg(%) YoY	QoQ
Coal India	24,625.0	6.2	16.4	5,415.0	9.0	36.2	4,052.0	3.3	37.3
Graphite India	545.0	-15.2	12.4	27.0	LP	LP	50.0	LP	LP
ITC	12,559.8	4.6	4.9	4,522.6	-2.0	11.4	3,806.8	-8.1	17.8
ACC	4,264.8	7.4	20.6	699.3	55.3	4.2	410.6	50.3	12.9
Zee Ent.	2,091.2	2.1	21.4	554.2	-2.1	76.7	380.4	8.9	304.3
Petronet LNG	7,591.0	-14.8	21.7	1,215.4	9.7	-10.8	761.7	12.8	-17.9
KNR Construction	619.0	11.0	3.0	117.6	-5.4	-5.2	54.2	34.9	8.8
NCC	2,201.8	4.0	42.9	264.5	5.8	26.1	94.5	-14.3	61.8
Ashok Leyland	5,189.0	29.2	82.9	312.0	38.6	288.1	61.0	121.4	LP

Recent Releases	
Date	Report
February 10,2021	Result Update-AIA Engineering
February 10,2021	Company Update-Firstsource Solutions
February 10,2021	Result Update-Aster DM Healthcare
February 10,2021	Result Update-TCI Express
February 10,2021	Result Update-JK Cement





Pankaj Pandey

Head – Research pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
1st Floor, Akruti Trade Centre,
Road No 7, MIDC
Andheri (East)
Mumbai – 400 093
research@icicidirect.com



Disclaimer

ANALYST CERTIFICATION

I/We, Pankaj Pandey, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number - INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.